GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

povetacicept   Click here for help

GtoPdb Ligand ID: 14426

Synonyms: ALPN-303 | TACI vTD-Fc
Immunopharmacology Ligand
Compound class: Peptide
Comment: Povetacicept (ALPN-303) is a Fc fusion protein that contains a variant TACI domain of the TNFRSF13B receptor for the peptide cytokines B cell activating factor (BAFF; TNFSF13B) and a proliferation-inducing ligand (APRIL; TNFSF13) [2]. It functionally antagonises the cellular signalling pathways of these ligands via TNFRSF13B on B cells.
In the peptide sequence provided the TACI domain is amino acids 1-43, with a short linker (GSGGGGS 44-50 ) and the remainder being the Fc domain. The functional peptide is a dimer, linked by inter-chain disulphide bridges.
No information available.
Summary of Clinical Use Click here for help
Povetacicept (ALPN-303) was progressed as a clinical candidate for the treatment of autoimmune conditions including lupus nephritis (a secondary complication of systemic lupus erythematosus/SLE), and immunoglobulin A nephropathy (IgAN) [4].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05732402 An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases Phase 1/Phase 2 Interventional Alpine Immune Sciences, Inc.
NCT05757570 An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias Phase 1/Phase 2 Interventional Alpine Immune Sciences, Inc.
NCT06564142 Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) Phase 3 Interventional Alpine Immune Sciences, Inc.
NCT05034484 A Study of ALPN-303 in Adult Healthy Volunteers Phase 1 Interventional Alpine Immune Sciences, Inc. The RUBY-1 study 1